Therapeutic Antibody Market in China 2021
- Markverslag
- ID: HL10075C
- Afleweringstyd: 1 Werksdag
- Merk: Therapeutic Antibody
Beskrywing
The therapeutic antibody market in China in terms of revenue is set to grow by US$ 41 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 30.4% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix.
Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for therapeutic antibody. The China therapeutic antibody market is segmented on the basis of type. Volgens tipe, it is categorized into antibody-drug conjugate (ADC), BsAb, monospecific Ab, en ander.
The report has profiled some of the key players of the market such as 3SBio Inc., Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceutical Group Co. Bpk., Jiangsu Hengrui Medicine Co. Bpk., Merck KGaA, Novartis International AG, Roche Holding AG, Sinopharm Corporation Ltd..
Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the therapeutic antibody market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.
Verslag Omvang
Tik: antibody-drug conjugate (ADC), BsAb, monospecific Ab, en ander
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027
Sleutelvoordele vir belanghebbendes
Get a comprehensive picture of the China therapeutic antibody market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the therapeutic antibody market in China looks like
Identifiseer die mededingende landskap en geleentheidsvenster
INHOUDSOPGAWE
1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Therapeutic Antibody Market by Type
4.1 Antibody-Drug Conjugate (Adc)
4.2 Bsab
4.3 Monospecific Ab
4.4 Ander
5. Maatskappy profiele
5.1 3SBio Inc.
5.2 Bristol-Myers Squibb Company
5.3 Chengdu Kanghong Pharmaceutical Group Co., Bpk.
5.4 Jiangsu Hengrui Medicine Co., Bpk.
5.5 Merck KGaA
5.6 Novartis International AG
5.7 Roche Holding AG
5.8 Sinopharm Corporation Ltd.
6. Bylaag
6.1 Oor StrategyHelix
6.2 Vrywaring
USD 450